ARDX

Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for kidney and cardiorenal diseases. Headquartered in Waltham, Massachusetts, the company specializes in therapies that work in the gastrointestinal tract to address systemic disorders. Ardelyx's lead commercial product is IBSRELA (tenapanor), approved for the treatment of irritable bowel syndrome with constipation in adults. The company's primary development focus is XPHOZAH (tenapanor), which received FDA approval in September 2023 for controlling serum phosphorus in adults with chronic kidney disease on dialysis. XPHOZAH represents a novel, non-binder phosphate absorption inhibitor that reduces phosphate absorption in the gut. Ardelyx partners with Kyowa Kirin for the development and commercialization of tenapanor in Japan and certain Asia-Pacific territories. The company employs approximately 200 people and operates research facilities supporting its pipeline development. In addition to its tenapanor-based products, Ardelyx is advancing RDX013, a potassium secretagogue program targeting hyperkalemia. The company reported total revenue of $26.3 million in 2023, primarily from product sales and collaboration agreements. As a commercial-stage biopharmaceutical firm, Ardelyx focuses on cardiorenal therapeutic areas with significant unmet medical needs, positioning itself within the specialized nephrology treatment market.